UnitedHealthcare - 2014 to Present
Keytruda (pembrolizumab)
Drugs for Cancer : Drugs for Cancer
  • Derm: Acne Vulgaris:
    Documented Diagnosis: Yes
    Medical Test Required: No
    Reauthorization Required: No
    Duration of Reauthorization: N/A
    Limited to non-cosmetic use: No

  • Acromegaly, Neuroendocrine Tumor (NET):
    Duration: 1 year(s)
    Documented Diagnosis: Yes
    Medical Test Required: No
    Reauthorization Required: No
    Duration of Reauthorization: N/A

    Oncology: Carcinoid Syndrome:
    Duration: 1 year(s)
    Documented Diagnosis: Yes
    Medical Test Required: No
    Reauthorization Required: No
    Duration of Reauthorization: N/A
    Requires diagnosis of Carcinoid syndrome with diarrhea: Yes
    Concomitant Therapy Required with Somatostatin Analog Therapy: No
    Patient Required to Try Increased Dosage of Sandostatin: No